# EDGAR Filing Document

**Accession Number:** 0001838163
**File Stem:** 0001493152-26-027818
**Filing Date:** 2026-6
**Character Count:** 24589
**Document Hash:** 561cee4c46d20eed00bf65b49887c610
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-027818.hdr.sgml**: 20260609

**ACCESSION NUMBER**: 0001493152-26-027818

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260609

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260609

**DATE AS OF CHANGE**: 20260609

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Brand Engagement Network Inc.
- **CENTRAL INDEX KEY:** 0001838163
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40130
- **FILM NUMBER:** 261074512

**BUSINESS ADDRESS:**
- **STREET 1:** 300 DELAWARE AVE
- **STREET 2:** SUITE 210 #409
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801
- **BUSINESS PHONE:** 307-757-3650

**MAIL ADDRESS:**
- **STREET 1:** 300 DELAWARE AVE
- **STREET 2:** SUITE 210 #409
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DHC Acquisition Corp.
- **DATE OF NAME CHANGE:** 20201229

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or Section 15(d)**

**of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 9, 2026 (June 8, 2026)**

**Brand Engagement Network Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40130** | **98-1574798** |
| (State or other jurisdiction of<br> incorporation or organization) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **300 Delaware Ave,**<br> **Suite 210**<br> **Wilmington, DE** | **19801** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(307) 757-3650**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | BNAI | The Nasdaq Stock Market LLC |
| Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share | BNAIW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01 <u>Entry into a Material Definitive Agreement</u>**.

On June 8, 2026, Brand Engagement Network, Inc. (the "Company" or "BEN") entered into definitive agreements establishing INTERVENT Health AI, Inc. in the State of Delaware ("INTERVENT Health AI"), a healthcare artificial intelligence joint venture formed with INTERVENT International, LLC ("INTERVENT") to develop, deploy and commercialize AI-powered health coaching solutions utilizing BEN's conversational AI and INTERVENT's clinically validated health coaching methodologies, proprietary healthcare datasets and industry expertise.

Key terms include:

● Formation of a 50/50 joint venture between BEN and INTERVENT;

● Exclusive five-year North American commercialization, technology development and AI platform arrangement between INTERVENT Health AI and SKYE AI USA, LLC ("SKYE"), a wholly owned subsidiary of BEN, subject to agreed performance milestones;

● Proposed non-exclusive international reseller arrangements through BEN-affiliated entities in Latin America and Africa, pursuant to which INTERVENT Health AI is expected to receive 50% of gross revenues generated from such sales, after agreed commissions and business development expenses;

● BEN, through SKYE, is entitled to receive 35% of certain revenues generated by INTERVENT Health AI from software, services and commercialization activities under the North American commercialization arrangement, net of agreed commissions and third-party fees;

● Establishment of a Board of Directors consisting of one BEN-appointed director, one INTERVENT-appointed director and one mutually agreed independent director appointed by the founding shareholders; and

● Authorization of a capital structure consisting of 100,000,000 shares of Class A Common Stock and 10,000,000 shares of Class B Preferred Stock.

Pursuant to the Shareholder Agreement, BEN and INTERVENT each received 32,500,000 shares of Class A Common Stock, representing 50% of the issued and outstanding common equity of INTERVENT Health AI. An additional 30,000,000 shares of Class A Common Stock were reserved for future issuance, and 5,000,000 shares were reserved for a future long-term incentive plan. Additionally, BEN and INTERVENT each received 5,000,000 shares of Class B Preferred stock, valued at $1.00 per share, as consideration for pre-paid licenses to Health AI for use of the respective companies' intellectual property.

The Shareholder Agreement provides customary governance, pre-emptive rights and ownership protection provisions, including restrictions on issuances that would reduce either founding shareholder below specified ownership thresholds without approval.

In connection with the formation of INTERVENT Health AI, BEN, through SKYE, has agreed in principle and to the material terms of a Reseller and Services Agreement, pursuant to which BEN will be appointed the exclusive provider of certain AI platform development, training, deployment and related technology services for INTERVENT Health AI in North America, excluding Latin America, for an initial five-year term, subject to agreed performance milestones.

Additionally, INTERVENT Health AI has agreed to the material terms of proposed non-exclusive international reseller arrangements providing for the commercialization of INTERVENT Health AI services through BEN-affiliated entities in Latin America and Africa. Subject to the terms of the applicable reseller agreements, INTERVENT Health AI is expected to receive 50% of gross revenues generated from such sales, after deduction of agreed commissions and business development expenses.

The parties intend for INTERVENT Health AI to leverage BEN's conversational AI technologies together with INTERVENT International's proprietary healthcare assets, including clinical research datasets, telehealth coaching interactions with more than 2,000,000 people, care pathways and related intellectual property, to develop a suite of AI-driven health coaching products designed for direct-to-consumer, employer, healthcare and enterprise markets.

The foregoing description of the Shareholder Agreement is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed as an exhibit to this Current Report on Form 8-K.

**Item 9.01 <u>Financial Statements and Exhibits</u>**.

(d) Exhibits

&nbsp;&nbsp;&nbsp;&nbsp;● **10.1** [Founding Shareholders Agreement dated June 8, 2026, by and between Brand Engagement Network, Inc., and INTERVENT International, LLC.](ex10-1.htm)

● **104** Cover Page Interactive Data File (embedded within the Inline XBRL document).

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Brand Engagement Network Inc.** | **Brand Engagement Network Inc.** |
| Dated: June 9, 2026 | By: | */s/ Tyler Luck* |
|  | Name: | Tyler Luck |
|  | Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**SHAREHOLDER AGREEMENT**

**AGREEMENT OF THE FOUNDING SHAREHOLDERS** entered by **Brand Engagement Network, Inc. ("BEN")** and **INTERVENT INTERNATIONAL, LLC** ("**INTERVENT**"), as the Founding Shareholders of **INTERVENT Health AI, Inc.**, ("**Health AI**"), executed on June 8, 2026.

**WHEREAS**,

**A.** BEN
 and INTERVENT are the Founding Shareholders of Health AI, and represent the 100% of the stock
 currently issued to date by Health AI and together have full control of the shares issued
 and available.

**B.** Both
 parties want to collaborate for the success of Health AI, and the joint venture between them
 that Health AI represents,

**C.** Health
 AI was created for the creation, deployment and commercialization of a suite of "Stand-Alone
 AI Health Coach" product offerings,

**D.** And
 for that purpose, both parties will provide access to Health AI to resources, both technical
 and information, as well as mutual and reciprocal cooperation,

**THEREFORE**, the parties, **AGREE** as follows:

**1.** **Stock Issuance.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.1.** Health
 AI is authorized to issue a total number of 100,000,000 shares of Class A Common Stock, at
 a par value of 0.0001 USD each, to be allocated as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.1.1.** BEN
 - 32,500,000 shares (which currently represents 50% of the issued and outstanding shares)

**1.1.2.** INTERVENT
 – 32,500,000 shares (which currently represents 50% of the issued and outstanding shares)

**1.1.3.** 30,000,000
 shares shall be reserved and subject to approval by the Board of Directors of Health AI

**1.1.4.** Long
 Term Incentive Plan (LTIP) – 5,000,000 shares reserved and subject to the LTIP to be
 adopted by the Board of Directors of Health AI.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.2.** Health
 AI is authorized to issue a total number of 10,000,000 shares of Class B Preferred Stock
 at a par value of $1.00 USD each, to be allocated in favor of BEN and INTERVENT as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.2.1.** BEN
 – 5,000,000 shares

**1.2.2.** INTERVENT
 – 5,000,000 shares

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.3.** BEN
 and INTERVENT shall have pre-emptive rights but no obligation to participate in new issuances
 pro-rata. No new shares of common stock will be issued without BEN's and INTERVENT's
 approval if the issuance would dilute either BEN or INTERVENT, respectively, below 20% without
 compensation.

**2.** **Board of Directors.** The Board of Directors shall
 consist of three directors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.1.** Each
 party will designate a member of the Board of Directors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.1.1.** INTERVENT
 appoints and designates Neil F. Gordon, MD, PhD, MPH as its Member of the Board

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.1.2.** BEN
 appoints and designates, James D. Henderson, Jr. as its Member of the Board

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.1.3.** The
 third member of the Board shall be a neutral individual as mutually agreed between BEN and
 INTERVENT.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.2.** The
 Chairman of the Board of Health AI will be Neil F. Gordon, MD, PhD, MPH.

**3.** **Project.** BEN and INTERVENT will (and will cause their respective affiliates to) cooperate with each
 other and with Health AI to facilitate the conceptualization, design, training, development,
 commercialization and continuous improvement of a suite of "StandAlone AI Health Coach"
 product offerings, as defined in Section 4.2 (the "Project").

**4.** **Licenses and Agreements.** The parties agree that for the operation of Health AI, each party will
 execute agreements with Health AI, as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.1.** BEN
 via its subsidiary, SKYE AI USA, LLC, shall enter into a license with Health AI for the specific
 purpose of establishing AI enabled technological solutions for an AI enabled health coaching
 platform sufficient to achieve various "Stand-Alone AI Health Coach" product
 offerings (the "Health Coaching Platform"), for the North America territory and
 other geographies as mutually agreed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.1.1.** BEN
 and SKYE AI USA, LLC, shall have a minimum five (5) year exclusivity from Health AI for the
 training, development and designated services for deployment of the Health Coaching Platform.
 The exclusivity will remain in effect if certain mutually agreed upon milestones continue
 to be met.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.1.2.** Health
 AI shall have a minimum five (5) year exclusivity from SKYE AI USA and BEN, for use of BEN's
 licensed IP and Software. The exclusivity will remain in effect if certain mutually agreed
 upon milestones continue to be met.

**4.1.3.** After
 deducting any mutually agreeable sales, promotion, and business development commissions and
 other fees payable by Health AI to brokers or other third parties, and as more fully described
 in a reseller agreement, Health AI will pay to SKYE AI USA a fee of 35% (thirty five percent)
 of all relevant revenue from the software, services or sales earned and collected.

**4.1.4.** SKYE
 AI USA shall submit a Statement of Work (SOW) to Health AI for the Health Coaching Platform
 for any client-related software or services and Health AI shall pay the agreed upon sum upon
 execution of any Health AI and INTERVENT approved SOW to begin the project.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.2.** INTERVENT
 shall enter into a license with Health AI for exclusive use of its relevant intellectual
 property assets, including its research-quality datasets, audited telehealth coaching interactions,
 proprietary care algorithms and pathways, and participant facing content, together with the
 permission and ability to reference and leverage its clinical/industry credibility, extensive
 body of published outcomes data, and strategic relationships, for the training, development
 and/or commercialization of a suite of "StandAlone AI Health Coach" product offerings.
 It is intended that these offerings will facilitate the widespread deployment of a suite
 of AI-driven health guidance and coaching product offerings specifically designed for delivery
 directly to multiple classes of end users, ultimately without reliance upon human coaches
 or clinicians as the core service delivery mechanism.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.2.1.** Health
 AI shall have a minimum five (5) year exclusivity from INTERVENT for the use of INTERVENT's
 relevant database, and other designated intellectual property assets, and for the commercialization
 and consulting services for the Health Coaching Platform in North America and mutually agreed
 geographies. The exclusivity will remain in effect if certain mutually agreed upon milestones
 continue to be met.

**4.2.2.** Health
 AI will pay to INTERVENT agreed upon sums under one or more SOWs to provide the support in
 developing, training and operating the AI models to develop the "Stand-Alone AI Health
 Coach" product offerings and associated Health Coaching Platform.

**4.2.3.** If
 Health AI provides human health coaching services, it shall exclusively engage the service
 of INTERVENT or an affiliate of INTERVENT, as the entity providing such human health coaching
 services for the North America market, and the services would be provided in accordance with
 the SOWs and mutually agreed fees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.3.** **Health AI** will enter into reseller agreements, for the provision for the "Stand-Alone
 AI Health Coach" product offerings and associated Health Coaching Platform, with the
 following entities and general conditions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.3.1.** Health
 AI will enter into a non-exclusive reseller agreement with **SKYE Salud, S.A. de C.V.**,
 a company existing under the Laws of Mexico, for the resale of its services in Mexico, and
 Latin America. After deducting any mutually agreeable sales and business development commissions
 payable by SKYE Salud to salespeople or other third parties, and as more fully described
 in the reseller agreement, Health AI shall receive 50% (Fifty percent) of all gross revenue
 from the sale of Health AI's services.

The services of SKYE Salud, includes an AI Enabled Health information platform, focused on Health Professionals and Health Public and Private companies, and the parties agree that these services may be provided with Health AI's services and do not imply competition between them.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.3.2.** Health
 AI will enter into a non-exclusive reseller agreement with **SKYE Africa Intelligence, PTY LTD.**, a company existing under the Laws of South Africa, for the resale of its services
 in South Africa and the African Continent. After deducting any mutually agreeable sales and
 business development commissions payable by SKYE Africa Intelligence to salespeople or other
 third parties, and as more fully described in the reseller agreement, Health AI shall receive
 50% (Fifty percent) of all gross revenue from the sale of Health AI's services.

The services of SKYE Africa Intelligence include an AI-powered mental health initiative for University students, focused on mental health care, and the parties agree that these services may be provided with Health AI's services and do not imply competition between them.

**5.** **Investment.** Provided that the agreements contemplated by Sections 4.1 and 4.2 of this Founding Shareholders
 Agreement have been executed, Health AI is anticipated to be valued at no less than $25,000,000.00
 USD for the initial seed funding round (when combining the shares described in Section 1.1).
 Health AI shall promptly prepare a Stock Purchase Agreement within (5) business days of execution
 of the agreements contemplated by Sections 4.1 and 4.2 of this Founding Shareholders Agreement.
 Execution of the Stock Purchase Agreement shall secure the initial segment of the seed funding
 by investors identified by BEN for the sum of $1,000,000.00 USD (in exchange for 4,000,000
 of the 30,000,000 shares described in Section 1.1.3), at the mutually agreed upon valuation
 of not less than $25,000,000.00 USD, as established by the Board of Directors.

Added funding from investors above the initial sum of $1,000,000.00 USD, shall be at a mutually agreed upon valuation of not less than $25,000,000.00 and other terms and conditions, as established by the Board.

This investment will be used to pay for sums under the SOWs agreed between the parties to begin the stated Project, as well as any SOW agreed to with any new customer. Finally, the investment will also provide the mutually approved working capital for Health AI for its operations.

**6.** **Cooperation.** Both parties will cooperate and perform in good faith on any issue for the success of Health
 AI and the stated Project, providing all resources reasonably necessary to the completion
 of the Project, and the sale of services and licenses from the Project.

**7.** **Non-Compete.** Including the exclusivities included in the agreed licenses, for so long as they are shareholders
 and for a period of 12 months thereafter, both parties shall not generate, agree on or permit
 a competing product, project or use of the agreed assets that might compete with the Project,
 the assets, services and software of either of the parties or Health AI, without the express
 written consent of the other party.

**8.** **Mediation.** In any case of disagreement or breach if this agreement both parties shall mediate the breach
 or disagreement to find a mutually agreed solution to the issue.

**9.** **Exit Strategies.** In the event a conflict arises between the Founding Shareholders, its operation
 or the Project, and after attempt at mediation or any other dispute resolution process, or
 after 7 (seven) years from incorporation, both parties agree to try to sell or buy from the
 other its full equity in Health AI, or sell those shares to Health AI itself, and allow the
 remaining owner to operate Health AI.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.1.** In
 the event of a disagreement related to the fair market value of the Company, an independent
 valuation from a qualified entity as mutually agreed upon by the Founding Shareholders will
 be performed and paid for by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.2.** If
 a sale between the parties cannot be reached, both parties shall sell their shares to a mutually
 agreeable third party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.3.** The
 above exit strategies shall be deemed fully voided if:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.3.1.** The
 Company raises at least **$10,000,000.00 (Ten Million US Dollars)** in post incorporation
 capital funding; or,

**9.3.2.** The
 Company is valued by an independent third party to be at least **$50,000,000.00 (Fifty million US Dollars)**.

**10.** **Confidentiality.** Both parties agree to keep confidential this agreement, all information between the parties
 related to the obligations under this agreement, and all information of Health AI.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10.1.** "Confidential
 Information" means any and all information disclosed by either party to the other which
 is marked "confidential" or "proprietary" or which the recipient
 knows or has reason to know is regarded by the disclosing party as such, including oral information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10.2.** "Confidential
 Information" does not include any information that the receiving party can demonstrate
 was or is: (a) at the time of disclosure to it, in the public domain; (b) after disclosure
 to it, published or otherwise becomes part of the public domain through no fault of the receiving
 party; (c) in the possession of the receiving party at the time of disclosure to it; (d)
 received after disclosure to it from a third party who had a lawful right to disclose such
 information to it without any obligation of confidentiality; or (e) independently developed
 by the receiving party without reference to Confidential Information of the disclosing party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10.3.** The
 receiving party shall not be considered liable or in breach for disclosing Confidential Information
 which is required to be disclosed by judicial or governmental action; provided that prompt
 notice is given to the disclosing party wherever possible in order to enable it to seek a
 protective order or otherwise prevent such disclosure.

**BOTH PARTIES SHALL EXECUTE THE AGREEMENT BY DIGITAL SIGNATURE, FULLY AWARE OF THEIR OBLIGATIONS UNDER THE AGREEMENT.**

Brand Engagement Network, Inc.

---

| | |
|:---|:---|
| By: | /s/ Tyler Luck |
| Authorized Signatory: Tyler Luck, CEO | Authorized Signatory: Tyler Luck, CEO |

---

INTERVENT INTERNATIONAL, LLC.

---

| | |
|:---|:---|
| By: | /s/ Neil F. Gordon |
| Authorized Signatory: Neil F. Gordon, MD, PhD, MPH, CEO | Authorized Signatory: Neil F. Gordon, MD, PhD, MPH, CEO |

---